Search Follow us
Refine By

Stock Exchange

Analyst

Type of Publication

prescient

1 - 5 of 5
Sort by: popularity | newest
Page  of 1
Prescient Therapeutics

PTX-100 to target RhoA-mutant lymphomas

Update | Pharmaceutical & healthcare | 20 Nov 2017

Prescient Therapeutics is planning a clinical trial of PTX-100 in RhoA-mutant lymphomas, a niche indication where the company could potentially conduct a pivotal study before out-licensing. It has resumed recruitment in the Phase Ib component of trials of lead anti-cancer compound PTX-200 in acute myeloid leukaemia (AML) and ovarian cancer, and is working with the FDA to recommence its Phase II breast cancer study. The company had A$6.9m cash on 30 September, sufficient to fund operations into FY19. We value Prescient at A$62m or A$0.29 per share.

Prescient Therapeutics

AML trial for PTX-200 a valuable addition

Update | Pharmaceutical & healthcare | 02 Mar 2016

Prescient has sharpened its focus on lead anti-cancer compound PTX-200 and plans to add a Phase Ib trial in acute myeloid leukaemia (AML) to the ongoing Phase I/II trials in breast and ovarian cancers. It has raised ~A$2m through a share purchase plan and placement, which will fund operations until 2017. We raise our valuation to A$49m (A$0.53/share), with the addition of the AML indication for PTX-200 more than offsetting the deferral of Phase 1b trials for PTX-100.

Prescient Therapeutics

Two clinical trials underway, 3 more in the wings

Update | Pharmaceutical & healthcare | 28 Sep 2015

Prescient is developing two promising cancer compounds that target major tumour survival pathways. It has two Phase Ib/II trials underway, and plans to initiate three more over the next year. Recent positive results from Merck validate the mechanism of action of PTX-200, which targets Akt. Prescient requires additional funding to advance its drug development programme. Our valuation is A$36m, or A$0.62 per share (pre-funding).

Prescient Therapeutics

No time like the Pres(ci)ent

Initiation | Pharmaceutical & healthcare | 29 Apr 2015

Prescient acquired two promising cancer compounds that target major tumour survival pathways in 2014. The most advanced compound, PTX-200, is in Phase Ib/II trials in breast and ovarian cancers; interim data from the breast cancer study are expected in early 2016. Three additional Phase Ib/II trials are scheduled to start by June 2016, subject to funding. We value Prescient at A$35m or A$0.66 per share.

Prescient Therapeutics

Leveraged to newsflow

QuickView | Pharmaceutical & healthcare | 07 Jan 2015

Prescient acquired two promising cancer compounds that target major tumour survival pathways in 2014. The most advanced compound, PTX-200 (previously TCN-P), is in US government-funded Phase Ib/II trials in breast and ovarian cancers; interim data from the breast cancer study are expected to report in H215. Three additional Phase Ib/II trials are scheduled to commence in H115, subject to funding. Given Prescient's small EV, positive newsflow could offer significant upside.